Jianyuan Luo
Direktor/Vorstandsmitglied bei Continent Pharmaceutical Inc.
Aktive Positionen von Jianyuan Luo
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Continent Pharmaceutical Inc.
 Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Direktor/Vorstandsmitglied | 01.01.2019 | - |
| Independent Dir/Board Member | 01.01.2019 | - | |
| The Chinese Medical Association | Corporate Officer/Principal | 01.02.2013 | - |
Beijing Continent Pharmaceutical Co., Ltd.
 Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Direktor/Vorstandsmitglied | - | - |
| Independent Dir/Board Member | - | - |
Karriereverlauf von Jianyuan Luo
Ehemalige bekannte Positionen von Jianyuan Luo
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| University of Maryland | Corporate Officer/Principal | 01.05.2010 | 01.01.2015 |
Ausbildung von Jianyuan Luo
| Peking University | Undergraduate Degree |
| University of Kentucky | Doctorate Degree |
Statistik
International
| China | 5 |
| Vereinigte Staaten | 3 |
Operativ
| Director/Board Member | 2 |
| Independent Dir/Board Member | 2 |
| Corporate Officer/Principal | 2 |
Sektoral
| Consumer Services | 4 |
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Continent Pharmaceutical Inc.
Continent Pharmaceutical Inc. Pharmaceuticals: MajorHealth Technology Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China. | Health Technology |
| The Chinese Medical Association | |
Beijing Continent Pharmaceutical Co., Ltd.
Beijing Continent Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China. | Health Technology |
- Börse
- Insiders
- Jianyuan Luo
- Erfahrung